[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Alcoholic Hepatitis - Pipeline Review, H2 2019

November 2019 | 105 pages | ID: A7E00FA83CAEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Alcoholic Hepatitis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2019, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 9, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Alcoholic Hepatitis - Overview
Alcoholic Hepatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alcoholic Hepatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alcoholic Hepatitis - Companies Involved in Therapeutics Development
Afimmune Biopharma Ltd
Cadila Healthcare Ltd
DURECT Corp
Generon (Shanghai) Corp Ltd
Gilead Sciences Inc
Immuron Ltd
Intercept Pharmaceuticals Inc
Novartis AG
Pattern Therapeutics
PharmaKing Co Ltd
Vectus Biosystems Ltd
Verlyx Pharma Inc
Alcoholic Hepatitis - Drug Profiles
AF-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentamidine isethionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKM-02GI1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-7314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-4A32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alcoholic Hepatitis - Dormant Projects
Alcoholic Hepatitis - Discontinued Products
Alcoholic Hepatitis - Product Development Milestones
Featured News & Press Releases
Nov 12, 2019: DURECT announces positive results from the phase 2a clinical trial of DUR-928 in alcoholic hepatitis patients in a late-breaking presentation at The Liver Meeting
Nov 06, 2019: DURECT to host key opinion leader call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results
Oct 21, 2019: DURECT announces DUR-928 Phase 2a Alcoholic Hepatitis study results selected for late-breaking oral presentation at The Liver Meeting 2019
Sep 17, 2019: DURECT announces positive data from its Phase 2a clinical trial of DUR-928 in Alcoholic Hepatitis
Aug 08, 2019: Immuron reports results in severe alcoholic hepatitis clinical trial
Jun 18, 2019: DURECT announces completion of the 90 mg severe cohort and dose escalation committee approval to commence 150 mg dosing in patients with severe alcoholic hepatitis (AH) in its ongoing DUR-928 phase 2a AH trial
May 07, 2019: DURECT announces preliminary data from the ongoing DUR-928 alcoholic hepatitis phase 2a trial
May 03, 2019: DURECT to present preliminary data from the ongoing DUR-928 alcoholic hepatitis phase 2a trial and report first quarter 2019 financial results
Jan 07, 2019: DURECT provides update on its lead product candidate DUR-928
Nov 19, 2018: DURECT announces amendment to accelerate ongoing phase 2a trial of DUR-928 in alcoholic hepatitis (AH) by allowing dosing of severe AH patients in parallel to moderate AH patients
Nov 13, 2018: Generon's F-652 Shows Positive Results in "An open label, cohort dose escalation study to assess the safety and efficacy in patients with Alcoholic Hepatitis"
Apr 25, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
Nov 23, 2015: Generon Collaborating with Mayo Clinic to Initiate a Phase IIa Study with F-652, a First-in-Class Biologic, to Treat Patients with Alcoholic Hepatitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Table 1: Number of Products under Development for Alcoholic Hepatitis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Alcoholic Hepatitis - Pipeline by Afimmune Biopharma Ltd, H2 2019
Table 11: Alcoholic Hepatitis - Pipeline by Cadila Healthcare Ltd, H2 2019
Table 12: Alcoholic Hepatitis - Pipeline by DURECT Corp, H2 2019
Table 13: Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2019
Table 14: Alcoholic Hepatitis - Pipeline by Gilead Sciences Inc, H2 2019
Table 15: Alcoholic Hepatitis - Pipeline by Immuron Ltd, H2 2019
Table 16: Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2019
Table 17: Alcoholic Hepatitis - Pipeline by Novartis AG, H2 2019
Table 18: Alcoholic Hepatitis - Pipeline by Pattern Therapeutics, H2 2019
Table 19: Alcoholic Hepatitis - Pipeline by PharmaKing Co Ltd, H2 2019
Table 20: Alcoholic Hepatitis - Pipeline by Vectus Biosystems Ltd, H2 2019
Table 21: Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc, H2 2019
Table 22: Alcoholic Hepatitis - Dormant Projects, H2 2019
Table 23: Alcoholic Hepatitis - Discontinued Products, H2 2019

LIST OF FIGURES

Figure 1: Number of Products under Development for Alcoholic Hepatitis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

Afimmune Biopharma Ltd
Cadila Healthcare Ltd
DURECT Corp
Generon (Shanghai) Corp Ltd
Gilead Sciences Inc
Immuron Ltd
Intercept Pharmaceuticals Inc
Novartis AG
Pattern Therapeutics
PharmaKing Co Ltd
Vectus Biosystems Ltd
Verlyx Pharma Inc


More Publications